5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Wanbury Ltd.

•
wanbury.comBSE: 524212NSE: WANBURY
Market Cap₹ 837 Cr.
Current Price
High / Low₹ 359 / 162
Stock P/E19.5
Book Value₹ 19
Price to Book14.96
Dividend Yield0.00 %
ROCE36.0 %
ROE84.2 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has a healthy return on capital (ROCE) of 55.8%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 28.1%
  • Promoters have been increasing their shareholding - up 3.2pp over 2 years
  • Latest quarter profit grew 1200.9% YoY, showing strong momentum
  • Operating margins have improved to 11.2% from 7.2%

CONS

  • Company has a high debt-to-equity of 3.37x
  • Recent results are weak - TTM profit is down 38.0% versus prior year
  • A large part of profit comes from other income (41.0% of PBT)
  • Receivables are growing faster than sales - a possible quality concern
  • Interest coverage is weak at 1.8x - earnings barely cover interest

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.WANBURY239.5019.48837.460.0013.491200.87163.1824.4635.9714.98
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
117124126133146144146140131161133172163
120118119119133127124121120141120142139
Operating Profit-36614131721191120143024
OPM %-2.60%4.51%5.13%10.66%9.13%12.00%14.54%13.25%8.37%12.41%10.45%17.23%14.98%
210-31112612120
Interest347868878101098
Depreciation3333333333334
Profit before Tax-7-1-315710341811914
Tax %2.78%-25.35%-7.62%-10.87%6.01%-2.50%-0.19%0.80%0.00%1.84%5.43%-6.30%0.88%
Net Profit00000710341812013
-2.22-0.27-1.000.311.432.253.1410.280.322.440.386.184.12

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
423434371391367393511500578600630
391415439378389377479477506532542
Operating Profit3219-6813-22163223726888
OPM %7.65%4.27%-18.30%3.42%-5.88%3.99%6.21%4.62%12.48%11.29%13.98%
1907712129581026125
Interest3236314033232121293737
Depreciation910101010101112131314
Profit before Tax-762-32-2565-1281-10563042
Tax %-0.00%0.61%1.17%0.55%0.32%-1.61%-0.43%-1.06%0.68%-3.31%-2.04%
Net Profit-762-32-2564-1381-10563143
EPS0.000.000.000.000.00-5.041.58-3.1817.099.32—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
9%
5 Years:
10%
3 Years:
5%

COMPOUNDED PROFIT GROWTH

10 Years:
25%
5 Years:
-14%
3 Years:
-28%

STOCK PRICE CAGR

10 Years:
18%
5 Years:
24%
3 Years:
59%
1 Year:
-10%

RETURN ON EQUITY

10 Years:
8%
5 Years:
17%
3 Years:
28%
Last Year:
84%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

No bonus data found

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital20232424252533333333
Minority Interest27000000000
-221-176-209-233-169-182-57-67-1219
3332171822521771657167103167
Trade Payables8614083112122134180149163138
1432051891271201421211175150
Total Liabilities388409269283275284347298338407
180186178172164167167167167201
Capital Work in Progress141010914112235
35341319122550223638
0000000089114
Cash & Bank79651712254613
151169627769691021033736
Total Assets388409269283275284347298338407

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
4343333044184120526
Cash from Investing-20-13-1-36481-9-17-51
Cash from Financing-28-27-33-27-108-17-29-321426
-53-2-0-0713-2121

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
39.7939.7739.7639.7639.6343.0943.0743.0243.02
0.221.020.841.551.590.820.720.590.89
0.000.000.000.000.000.000.000.000.06
Government0.000.000.000.000.000.000.000.000.00
59.9859.2059.4058.6858.7856.0856.2156.3956.03

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-02
Copy of Newspaper Publication

2026-09-02 - Wanbury Limited has informed the Exchange about Copy of Newspaper Publication: Information regarding 38th Annual General Meeting to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM).

2026-08-31
Record Date

2026-08-31 - Wanbury Limited has informed the Exchange that Record date for the purpose of Meeting is 18-Sep-2026.

2026-08-31
Shareholders meeting

2026-08-31 - Wanbury Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026

2026-08-28
Copy of Newspaper Publication

2026-08-28 - Wanbury Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-13
Press Release

2026-08-13 - Wanbury Limited has informed the Exchange regarding a press release dated August 13, 2026, titled "Press Release regarding EDQM Approval for new product Rivaroxaban API,USFDA DMF Clearances".

2026-08-11
Press Release

2026-08-11 - Wanbury Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Press release on Un-audited Financial Results for the quarter ended 30 June, 2026".

2026-08-11
Allotment of Securities

2026-08-11 - Wanbury Limited has informed the Exchange regarding allotment of 27530 securities pursuant to ESOP/ESPS at its meeting held on August 11, 2026

2026-08-11
Change in Management

2026-08-11 - Wanbury Limited has informed the Exchange about change in Management

2026-08-11
Outcome of Board Meeting

2026-08-11 - Wanbury Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

News

Recent coverage and analyst commentary for WANBURY

Loading news…

🤖

AI Stock Analyst

Wanbury Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login